Strategic Acquisition Asahi Kasei Group has acquired AiCuris for approximately €780 million/$919 million, signaling strong valuation and potential for expanded collaboration, distribution, and integration of AiCuris’ antisense, antiviral, and immunocompromised-focused therapies into larger partner networks.

Pritelivir Upside Pritelivir is in pivotal Phase 3 trials for recurrent and resistant HSV infections in immunocompromised patients, with recent presentations and FDA priority review indicating near-term regulatory milestones and potential for accelerated market access.

PREVYMIS Partnership Flagship product PREVYMIS is marketed by MSD, illustrating an established commercial pathway in CMV management for transplant recipients and offering potential for co-promotion, expansion of indication, or parallel partnerships in related immunocompromised infection indications.

Clinical Momentum Frequent high-profile presentations at ESCMID, ID Week, Tandem Meetings, and World Transplant Congress demonstrate an active clinical program with ongoing data generation, creating multiple entry points for investigator-initiated studies, collaborations, and grant-funded opportunities.

R&D Expansion Aicuris maintains a growing pipeline including AIC468 and antisense BK virus programs, plus an expanded leadership team (new CSO) and clinical development activity, suggesting opportunities to cross-sell platform technologies, companion diagnostics, or service collaborations to accelerate development timelines.